InVitae Corp (NVTA) Holdings Held by Royce & Associates LP
Royce & Associates LP held its stake in shares of InVitae Corp (NASDAQ:NVTA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 156,412 shares of the medical research company’s stock at the end of the 2nd quarter. Royce & Associates LP owned 0.37% of InVitae Corp worth $1,495,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Verity Asset Management Inc. acquired a new stake in InVitae Corp in the 1st quarter worth about $116,000. Donald L. Hagan LLC raised its stake in InVitae Corp by 30.0% in the 2nd quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock worth $124,000 after purchasing an additional 3,000 shares in the last quarter. Nationwide Fund Advisors raised its stake in InVitae Corp by 21.1% in the 1st quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock worth $189,000 after purchasing an additional 2,987 shares in the last quarter. American International Group Inc. raised its stake in InVitae Corp by 31.3% in the 1st quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after purchasing an additional 4,090 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in InVitae Corp in the 1st quarter worth about $200,000.
NVTA has been the subject of several analyst reports. ValuEngine upgraded shares of InVitae Corp from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. BidaskClub upgraded shares of InVitae Corp from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $15.00 price objective (up previously from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. Finally, Zacks Investment Research upgraded shares of InVitae Corp from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $12.94.
InVitae Corp (NASDAQ:NVTA) opened at 9.22 on Friday. InVitae Corp has a 12 month low of $5.76 and a 12 month high of $10.96. The stock has a 50 day moving average of $9.36 and a 200 day moving average of $9.99. The firm’s market capitalization is $401.48 million.
InVitae Corp (NASDAQ:NVTA) last issued its earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). The business had revenue of $14.34 million for the quarter, compared to the consensus estimate of $13.31 million. InVitae Corp had a negative return on equity of 153.27% and a negative net margin of 199.20%. InVitae Corp’s revenue for the quarter was up 157.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.77) EPS. On average, equities analysts predict that InVitae Corp will post ($2.35) earnings per share for the current fiscal year.
InVitae Corp Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Want to see what other hedge funds are holding NVTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InVitae Corp (NASDAQ:NVTA).
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.